← All trials
NCT06569381
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 23, 2024
- Primary completion
- Sep 9, 2024
- Completion date
- Dec 24, 2024
- First posted
- Aug 26, 2024
- Last posted
- Aug 26, 2024
- Enrollment
- 18
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Overseas Pharmaceuticals, Ltd.Lead sponsor
- Qingdao UniversityOfficial
- Shanghai ShouYan Clinical Development Co.,Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.